Yale University

EliScholar – A Digital Platform for Scholarly Publishing at Yale
Yale Medicine Thesis Digital Library

School of Medicine

January 2014

Medication Persistence In The Treatment Of Hiv
Infection: A New Construct For Hiv Research And
Clinical Care
Jason Bae
Yale School of Medicine, jason.bae@yale.edu

Follow this and additional works at: http://elischolar.library.yale.edu/ymtdl
Recommended Citation
Bae, Jason, "Medication Persistence In The Treatment Of Hiv Infection: A New Construct For Hiv Research And Clinical Care"
(2014). Yale Medicine Thesis Digital Library. 1856.
http://elischolar.library.yale.edu/ymtdl/1856

This Open Access Thesis is brought to you for free and open access by the School of Medicine at EliScholar – A Digital Platform for Scholarly
Publishing at Yale. It has been accepted for inclusion in Yale Medicine Thesis Digital Library by an authorized administrator of EliScholar – A Digital
Platform for Scholarly Publishing at Yale. For more information, please contact elischolar@yale.edu.

Medication Persistence in the Treatment of HIV Infection:
A New Construct for HIV Research and Clinical Care

A Thesis Submitted to the
Yale University School of Medicine
in Partial Fulfillment of the Requirements for the
Degree of Doctor of Medicine

by
Jason Woonghwan Bae
2014

MEDICATION PERSISTENCE IN THE TREATMENT OF HIV INFECTION: A
NEW CONSTRUCT FOR HIV RESEARCH AND CLINICAL CARE. Jason W.
Bae, Eileen C. Ing, Duncan S. Maru, William Guyer, Kristy Grimm, and Frederick
L. Altice. Section of Infectious Diseases, Department of Internal Medicine, Yale
University, School of Medicine, New Haven, CT
Adherence to therapy has dominated clinical and investigational conversation on
how HIV patients take medications. Adherence, although a critical concept in
medication-taking behavior, is becoming increasingly limited in its relevance to
patient outcomes as treatment regimens and our understanding of antiretroviral
resistance development evolve over time. In this thesis, a new construct of HIV
medication-taking behavior called ‘persistence’ is introduced and defined, in order
to provide researchers and practitioners with a more comprehensive understanding
of patient behavior and achieve better health outcomes. Literature review of
adherence, persistence, viral suppression, development of antiretroviral resistance is
performed here to reveal patient, medication, and healthcare setting characteristics
associated with suboptimal persistence. Impact of persistence on resistance
development and clinical outcomes is also summarized. Finally, patterns of nonpersistence among HIV-infected drug users undergoing directly-administered
antiretroviral therapy in a prospective, randomized-controlled trial are presented
along with factors associated with non-persistence. This study suggests that
decreased persistence for HIV treatment, or shorter duration on therapy, is
associated with increased rates of virological failure, development of antiretroviral
resistance, and increased morbidity and mortality. Additionally, frequency and
duration of non-persistent episodes rather than adherence may be a better predictor
of clinical outcomes in HIV-infected patients on certain regimens. More emphasis on
persistence when considering HIV medication-taking behavior in both clinical and
research setting is warranted.
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1. Introduction
Multiple terms, oftentimes expressing different constructs yet with some
overlap, have been used to explain how well a patient takes their medications.
These terms, such as adherence, compliance, persistence, and durability, are
often used interchangeably, sometimes lead to inaccurate or imprecise
interpretation of patient behavior, and may result in incorrect conclusions about
which intervention should be appropriately deployed. Much of the early
research and attention to medical management of HIV/AIDS has been focused
on the construct of adherence. Especially early in the HIV/AIDS epidemic when
regimens were often complicated, had large pill burdens, complex dosing
schedules, and low genetic barriers to resistance, adherence played an important
role in HIV treatment. Indeed, a large body of literature has repeatedly
demonstrated the importance of adherence, where a high level of adherence to
antiretroviral therapy was associated with successful viral suppression and
decreased morbidity. Treatment strategies, however, have changed.

In

recognition of the changing HIV epidemic and the various subpopulations
globally who will eventually access contemporary combination antiretroviral
therapy (cART), we provide insight into additional considerations and define the
construct of persistence, and its operationalization for clinical care and research
in the context of HIV treatment. Additionally, we summarize methods for
determination of persistence and current literature on persistence in HIV
treatment.
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The Dynamics of HIV Replication and Impact on Treatment
Decreased adherence to or discontinuation of a prescribed therapy is
likely to result in unfavorable health outcomes in chronic diseases, such as
hypertension, hyperlipidemia, congestive heart failure, or chronic obstructive
pulmonary disease. Management of HIV differs from other chronic diseases in
that successful control of the disease is more complex and also the consequences
of failure may be greater. First, suppression of viral replication requires lifelong
retention on cART, often consisting of 3 or more medications. Second, unlike in
hypertension or diabetes, inconsistent use of medications leads to development
of resistance to one or more medications in the regimen, thereby limiting future
treatment options and complicating therapy. Last, failure to suppress viral
replication not only affects the health of the patient, but also increases the risk of
HIV transmission to others who engage in high risk behaviors, posing greater
public health concerns than with non-communicable diseases.
Management of HIV has changed dramatically in recent years. Lessons
learned from the SMART trial where subjects randomized to discontinue cART
until pre-specified CD4 thresholds were met had increased non-HIV and HIVrelated morbidity and mortality compared to those who continuously remained
on therapy (1). This finding emphasizes more than ever that “remaining” on
therapy is crucial, and so is the need for interventions that allow treatment to
“persist over time.”
Antiretroviral treatment itself has also changed. Development of highly
potent, once-daily, low pill burden, and more tolerable cART has greatly
improved and altered the landscape of contemporary HIV management (2).
Contemporary regimens are affected less by perturbations in adherence, in part
2

due to the high genetic barrier to resistance by some medications (e.g., ritonavirboosted protease inhibitors) and long half lives of others (e.g., non-nucleoside
reverse transcriptase inhibitor, NNRTI). For example, nevirapine, a NNRTI, has a
serum half-life of 48 hours (3) and its serum level remains detectable 1 week after
discontinuation (4). On the other hand, abacavir and lamivudine, nucleoside
reverse transcriptase inhibitors (NRTI), have much shorter serum half-lives of 1.5
and 6 hours, respectively (5, 6) and the intracellular concentration of the active
abacavir metabolite becomes undetectable within 72 hours after the last dose (7).
Therefore, discontinuation of a multi-drug regimen such as the one above for 3
days or more may result in extended nevirapine monotherapy, during which
selective pressure on viral replication may result in development of resistance
due to the low genetic barrier to resistance by NNRTIs (8). In the case of
nevirapine administered even as a single-dose monotherapy regimen to prevent
mother-to-child-transmission of HIV, high rates of NNRTI resistance have been
observed among mothers and infants (9, 10). Efavirenz, a preferred NNRTI
component of contemporary regimens, also has a prolonged serum half-life of
40-55 hours, and like nevirapine, can remain at a therapeutic dose for longer than
21 days after discontinuation (11).

Pharmacokinetic profiles of NNRTIs like

efavirenz and nevirapine have the benefit of continuing to suppress HIV
replication when medications are stopped briefly, but may be detrimental when
treatment regimens are discontinued for longer periods due to their low genetic
barrier to resistance when HIV replication is not completely suppressed.
Ritonavir-boosted protease inhibitor regimens, also part of preferred
cART regimens, do not have prolonged serum half-lives like NNRTIs. These
antiretroviral agents, however, have other pharmacological advantages due to
3

their high genetic barrier to resistance such that even prolonged periods of
monotherapy potently suppress HIV replication, yet seldom result in the
development of resistance mutations (12, 13). As such, they pose few problems
when there is poor adherence or decreased persistence.
In a proof-of-concept pilot study, subjects who were on a suppressive
once-daily antiretroviral regimen were changed to five days on treatment and
then provided with a two-day holiday (72 hours since last dose); all subjects on
an efavirenz-containing regimen and 90% of those on a nevirapine-containing
regimen had suppressed HIV-1 RNA levels at 48 weeks suggesting that intervals
< 72 hours do not negatively impact clinical outcomes (14). On the other hand,
two out of nine subjects on a PI-based regimen had experienced virological
rebound by 48 weeks. In another trial, where antiretroviral therapy was
interrupted every other week in a “1 week on, 1 week off” strategy, 1 of 8
patients on an efavirenz-based regimen experienced virological failure with a
resultant new resistance mutation to efavirenz. In contrast, 11 of 17 patients on a
regimen containing ritonavir-boosted-saquinavir experienced virological failure,
however, none developed a new resistance mutation to a PI (15). These studies
suggest that the duration for which therapy may be discontinued without
expecting an adverse outcome differs depending on antiretroviral composition of
a regimen. This “permissible gap” (see below for definition) is most likely to be
between 2 to 7 days for a regimen containing efavirenz, but further investigations
are needed to better characterize the permissible gap that results in adverse
consequences.
Adherence, rather than persistence, has been the center of focus in
research of medication-taking behaviors among HIV-infected patients (see below
4

for definition). Contrary to the pervasive view that low adherence leads to
development of resistance, data suggest that the relationship between adherence
and resistance may be more complex (16), particularly when contemporary
preferred regimens are prescribed (Figure 1). For example, NRTI and PI
resistances were observed predominantly in highly adherent individuals in a
cohort study (17). In other studies, development of resistance to PIs was limited
to individuals with adherence greater than 90% (18) and imperfect adherence of
many ritonavir-boosted PI-containing regimens does not result in significant
levels of resistance (19). Emerging data from recent studies question the longtaught principle that “non-adherence leads to development of resistance and
virological failure” and also the construct of adherence itself and its applicability
in the current setting of HIV treatment.
In sum, adherence alone when using contemporary treatment regimens
may be insufficiently predictive of clinical outcomes in HIV-infected patients and
is dependent on the type of regimen prescribed. Clinical care and research in the
management of HIV would therefore benefit from an additional “timedependent” measure of medication-taking behaviors.

2. Aims
The purpose of this thesis is to introduce the construct of medication persistence
for HIV and present patterns of and characteristics associated with medication
persistence.

Specific Aims
5

1)

Define the construct of medication persistence in the setting of HIV
treatment and propose methods for determining persistence.

2)

Using a review of available literature;
2A)

Describe patterns of medication non-persistence and their impact
on development of antiretroviral resistance and clinical outcomes.

2B)

Describe patient, medication, and healthcare settings characteristics
associated with persistence.

3)

In a retrospective analysis of a randomized controlled trial of directlyadministered anti-retroviral therapy (DAART) vs. self-administered
therapy (SAT);
3A)

Describe patterns of medication among HIV-infected drug users
undergoing DAART.

3B)

Present medication and patient characteristics associated with nonpersistence.

3C)

Explore the relationship between non-persistence and virological
success.

3. Methods
Literature Review and Definition of Persistence (AIMS 1 & 2)
PubMed and Medline database were searched jointly by Jason Bae and
Frederick Altice for literature review of adherence, persistence, durability and
their relationship with antiretroviral resistance, viral suppression, and mortality.
The original idea of the manuscript was suggested by Frederick Altice. Jason Bae
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developed and refined the construct of persistence in the setting of HIV
treatment. The manuscript was jointly written by Jason Bae and Frederick Altice.

Patterns of Non-Persistence and Associated Characteristics from Project Trust (AIM 3)
Persistence data from Project Trust (National Institutes on Drug Abuse
R01 DA13805) were obtained as following. A 6-month, randomized controlled
study of directly-administered antiretroviral therapy (DAART) was conducted
among 141 drug users led by Frederick Altice. Primary outcomes of this project
are published elsewhere (20). Participants were recruited from all of the HIV
clinics in New Haven, Connecticut. Entry criteria included: (1) being HIV
seropositive; (2) being eligible for and/or being prescribed antiretroviral
medications; (3) residing within the city of New Haven; (4) active use of heroin
and/or cocaine in the previous 6 months; and (5) receiving no more than a twicedaily regimen. Following informed consent, eligible participants were
randomized 2:1 to DAART or self-administered therapy.
DAART participants received their antiretroviral medications at a mobile
health unit that traveled to four New Haven inner city neighborhoods on
weekdays (21). All medication doses were placed in small plastic bags in a
medication bottle with a Medication Electronic Monitoring System (MEMS)
Version 6 Smart Cap (Aardex). A trained outreach worker observed one daily
dose; all other doses were provided for the patient to take later, with a reminder
from a beeper. Weekend doses were dispensed on Fridays and each patient had
up to 3 days of an emergency supply of antiretroviral medications that were
stored in the MEMS bottle. In this study, only those participants who were
randomized to and initiated DAART were included in the analysis.
7

Virological success at 6 months for this predominantly antiretroviralexperienced population was defined a priori as having achieved an HIV-1 RNA
level reduction of at least 1.0 log10 copies/ml or an HIV-1 RNA level < 400
copies/ml at 6 months. Missing values were imputed as virological failure.
Persistence was calculated using a combination of daily DAART
observations and MEMS event data during the 6-month period of DAART.
Subjects were considered to be on treatment for a given day if either there was:
(1) an observed DAART dose or (2) a MEMS event. Missed DAART
appointments due to hospitalization or imprisonment were corrected from
verifiable clinical records of medication administration in these institutions.
Non-persistence was defined for three thresholds at any point during the
6-month intervention period: (1) ≥ 3 days (missing more than 2 consecutive days
of antiretroviral medications); (2) ≥ 5 days; and (3) ≥ 7 days. Once a participant
met the defined threshold gap, he or she was considered to be non-persistent. To
determine the recurrence and true extent of non-persistence, all interruptions in
treatment exceeding the proposed permissible gaps were considered to be nonpersistent episodes. Recurrent non-persistence was defined as having more than
one non-persistent episode, defined as gaps ≥ 3 days, within the 180-day
observation period of the study. Time to patient non-persistence was defined as
the number of days to the 1st day of a pre-defined first episode of nonpersistence. Patients who were lost to follow-up were considered non-persistent
from day of DAART discontinuation to day 180 of observation.
Regimen non-persistence was defined as any change in any component of
the initial antiretroviral medication regimen. Time to regimen non-persistence
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was measured as the number of days between DAART initiation and regimen
modification.
Baseline interviews assessed an array of psychosocial, demographic, and
drug use characteristics. Addiction severity was assessed using binary outcomes
(high severity if score ≥ 6) using the 10-item Drug Abuse Screening Test (DAST10), a self-report measure of problematic substance use, widely used for clinical
screening and research (22). The Center for Epidemiological Studies Depression
Scale (CES-D) (23), a 20-item self-report scale to measure depressive
symptomatology, is highly correlated with having major depression when scores
are ≥ 16. Participants’ attitudes towards DAART were also surveyed. Selfefficacy, which measures one’s sense of control over his life circumstances, was
assessed using the Self-Efficacy Form (24). Interviews were administered by nonclinical research assistants in research settings, but also included hospitals,
prisons and drug-treatment settings if necessary. Heavy drinking was defined as
more than two drinks per day for men and more than 1 per day for women on
average. Heavy cocaine use was defined as use for more than 5 days per month.
The following baseline demographic and psychosocial characteristics were
included in analysis: age, gender, race, homelessness, education, heavy drinking,
any cocaine use, heavy cocaine use, injection drug use, drug abuse severity, CESD score, social support, self-efficacy, confidence that one can take medications as
prescribed, preference for assistance with medication-taking, and willingness to
travel for DAART. In addition, frequency of dosing, pill burden, and baseline
viral load were included in analysis.
All statistical analyses, including creation of persistence variables using
the original dataset, were performed by Jason Bae and Eileen Ing using Stata SE
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(version 10.1, Stata Corp, TX, USA). Crude odds ratios were calculated using
bivariate logistic regression. Univariate variables with a P –value < 0.10 were
included in the multivariate logistic regression modeling, which were used to
calculate adjusted odds ratios. Firth’s penalized- likelihood logistic regression
was used for bivariate analyses when complete separation occurred (25). Time to
regimen non-persistence, stratified by the antiretroviral therapy based on the 1st
day of DAART, was plotted as Kaplan–Meier curves, and a hazard ratio was
calculated using Cox proportional-hazards regression.

4. Results
Definitions of Persistence in the setting of HIV Treatment
Adherence, the most frequent medication construct for HIV treatment, is
defined as “the extent to which a patient’s behavior corresponds with the
recommendations of a healthcare provider”, and is often synonymous with
compliance (26). In this thesis, we will use adherence to represent this construct.
When adherence refers to taking medication, it generally quantifies the extent to
which a patient acts in accordance with a prescribed interval and doses of a
prescribed regimen within a given time period (27). By definition, it is expressed
as a percentage of correctly timed doses (doses taken/doses prescribed x 100)
(27). Researchers and clinicians alike have tried to quantify the optimal level of
adherence (e.g., greater than 95%) needed to simultaneously suppress viral
replication and avoid development or resistance, yet these binary definitions
have not been borne to be equally predictive for differing cART regimens (16).
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Moreover, adherence thresholds have been plagued by measurement problems
(e.g., self-report, electronic monitoring, pharmacy refills) and with quantifying
exactly how much adherence is enough (16, 28).
Medication persistence, on the other hand, is also a medication-taking
construct defined as “the duration of time from initiation to discontinuation of
therapy (27).” By definition, it is expressed solely as a function of time, or the
number of days (or months) on treatment. Alternatively, persistence can be
expressed as a binary variable (persistent or non-persistent), measured at the end
of a pre-specified time period. Similar to adherence, defining persistence as a
binary variable is challenging due to the “permissible gap” in time that is
allowed to pass after discontinuation of a prescribed regimen that is associated
with a poor treatment outcome. Permissible gaps, however, are likely to differ
based on the type of cART regimen prescribed.
As with adherence, the concept of persistence may be applied to a variety
of situations including taking medications, following dietary advice, and
changing health habits.

Because persistence emphasizes the concept of

continuous therapy, a permissible gap, the maximum number of consecutive
doses that a patient can miss without expecting a reduced or suboptimal
outcome, should be pre-specified in any assessment of persistence.

Such

permissible gaps are ones that should have no negative clinical consequences for
patients.
Medication persistence and adherence are similar in that they both
measure the extent to which a patient’s behavior agrees with recommendations
of a healthcare provider.

They differ, however, in the dimensions of this

agreement. With regard to taking medications, adherence measures the
11

proportion of times that a patient takes medication as prescribed within a given
interval, whereas persistence measures the duration of time that a patient
continuously adheres to a prescribed regimen.

In other words, adherence

measures “how often”, whereas persistence measures “for how long.” As such,
these constructs are complimentary but distinct.
With regard to cART for the treatment of HIV, medication persistence
merits further categorization, including: patient persistence and regimen persistence.
Distinction between these constructs is described further.

Patient Persistence
According to the stringent definition of persistence as a continuous
therapy, a patient is persistent in adhering to the prescribed regimen as long as
the permissible gap is not exceeded. A permissible gap can be defined as the
maximum duration for which a patient may discontinue medication without
experiencing a suboptimal outcome or adverse consequence. Due to the high
replication capacity of HIV, the permissible gap for HIV treatment is likely to be
on the magnitude of days rather than weeks (see below); however, since cART
consists of multiple medications, often with different pharmacokinetic profiles,
the permissible gap may vary depending on individual medications within a
prescribed regimen. In addition, the duration of medication discontinuation
necessary for development of a suboptimal outcome may also vary depending
on the adverse consequence of interest (e.g. incomplete viral suppression,
development of resistance, development of an adverse clinical event). In the case
of viral suppression, a permissible gap may be on the order of days while the
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time to a clinical event (e.g., myocardial infarction or opportunistic infection) is
likely to be on the order of months to years.
If a patient discontinues medication for a period that exceeds the
permissible gap, the patient is no longer persistent with the HIV treatment. The
duration of non-persistence is equivalent to the time lapsed between the first
missed dose and re-initiation of therapy. A patient’s persistence with medication
is expressed as a continuous variable in days (or weeks) with the goal being a
lifetime.

Regimen Persistence
The concept of persistence may be extended beyond that of the individual
patient and be applied to an entire antiretroviral regimen. This concept is most
pertinent in resource-poor regions where available cART regimens are limited
and unlike contemporary regimens in resource-rich settings, are less tolerable,
have higher pill burdens and are pharmacologically inferior to newer regimens.
We define regimen persistence as “the duration between the initiation and
discontinuation of a specified antiretroviral regimen as agreed upon by the
patient and the healthcare provider.” Using this definition, any change in any
part of a regimen, for any reason, would result in the regimen being nonpersistent at the time of regimen discontinuation or modification.
In contrast to patient persistence—a measure of a patient’s continued
taking of cART, irrespective of the individual medications contained within the
regimen—regimen persistence measures duration of a particular cART regimen
as a means to suppress viral replication. Regimen persistence depends on factors
both intrinsic and extrinsic to the regimen. Intrinsic factors include adverse side
13

effects, pill burden, underlying levels of resistance to one or more components of
the regimen, and cost. Extrinsic factors, those that contribute to a change in the
components of the regimen, include new findings from clinical trials, new
treatment guidelines, and availability of antiretroviral medications in a particular
region. In contrast to patient persistence, the concept of a permissible gap is not
applicable in the definition of regimen persistence; a regimen is persistent as long
as it has not been explicitly modified or discontinued by either the patient or the
healthcare provider.

Patient Persistence, Regimen Persistence, and Adherence
While both are important, persistence and adherence are different but
inter-related, as illustrated in Figure 2. Adherence levels are indicated as a solid
line, and HIV-1 RNA levels are shown as a dashed line. Optimal HIV viral
suppression is observed when HIV-1 RNA levels fall below the dotted line. In
this example, a patient initiates an NNRTI-based regimen and initially achieves
virological

suppression.

Later,

however,

medications

are

discontinued

completely (patient non-persistence or 0% adherence), resulting in virological
rebound or replication to a detectable level. Alternatively, if the provider
discontinued medications for any reason (low supply, too costly, etc), the patient
would be persistent, the regimen would be non-persistent and the patient would
be 100% adherent since the patient did what the clinician recommended. Since
the patient has discontinued medications for a period exceeding the permissible
gap, he is no longer persistent with his original regimen; the patient is nonpersistent with medication for the duration between the first missed dose and the
next dose of medication he takes (patient non-persistence in Figure 1). The
14

duration of patient persistence, in this case, is defined as the time period between
the first dose and the last dose of the regimen [Patient (1) in Figure 1].
On the other hand, the regimen is persistent as long as it has not been
explicitly modified or discontinued through agreement between the patient and
the provider. Therefore, in this case, regimen persistence continues until the
provider changes the NNRTI-based regimen to a boosted protease inhibitor (PI)based one [Regimen (1) in Figure 1]. Patient persistence is not affected by the
regimen modification as long as the patient continuously adheres to medication
without exceeding the permissible gap; the second phase of patient persistence
[Patient (2) in Figure 1], which began with re-initiation of medication, continues
despite the modification in regimen.
As demonstrated in this example, a regimen may be persistent while the
patient is non-persistent. Likewise, a patient may be persistent with medicationtaking even when his regimen is changed as long as he continues to take his
prescribed medications. Finally, a patient may be persistent while achieving a
low level of adherence (sometimes defined as non-adherence). For example, if a
patient is prescribed medication twice daily, but takes the regimen once daily
everyday, he would be persistent but would maintain at a 50% adherence level.

Methods for Determining Persistence
Measurement of persistence and methods to collect persistence data have
been summarized previously (29, 30), and several methods may be used to
determine persistence in HIV treatment (See Table 1). Patient persistence can be
determined through measurements of a patient’s pill-taking history. These may
include direct observation, Medication Event Monitoring System (MEMS),
15

patient self-report recall, review of pharmacy refill and medical records. Regimen
persistence may also be determined using many of the same methods as in
patient persistence plus a regimen change form on a study instrument in a
prospective study. Reasons for patient or regimen non-persistence can be
measured via a study instrument that assesses these constructs or by review of
medical records.
Methods that yield high granularity of data, such as direct observation or
MEMS, often require prospective studies and are likely to be expensive.
Therefore, it is often impractical to gather this level of granularity in large
retrospective studies. On the other hand, pharmacy refill records can be obtained
with less cost and effort compared to other methods.

Pharmacy refill data,

however, lack sufficient detail to adequately measure patient persistence, cannot
accurately measure small permissible gaps in treatment, or answer why a
regimen is no longer persistent, but are often satisfactory to measure regimen
persistence per se.

Impact of Persistence on Clinical Outcomes
Patient Persistence
Patient non-persistence in HIV treatment has been insufficiently assessed
in current research and is associated with adverse clinical outcomes. In a Spanish
cohort study where the median duration of follow-up was 8.3 years, 43% of
patients had a treatment interruption longer than 3 days, and these patients had
a higher risk of treatment failure (31). In a Ugandan study with the median time
on therapy was 38 weeks, 23% of patients had a history of treatment interruption
greater than 4 days, which was significantly associated with virological failure
16

(32). Among injection drug users in Baltimore, 78% of subjects had one or more
treatment discontinuations, and 20% of the study population never resumed
cART (33).
In a study in which pill-taking history was measured using MEMS, 65% of
patients had a treatment interruption longer than 48 hours in the 24 weeks
observation period and were more likely to develop drug resistance than those
without an interruption (34). Similarly, patients with a history of more than one
drug holiday (patient non-persistence) lasting ≥ 48 hours were more likely to fail
therapy and develop a resistance to NNRTI-containing regimens compared to
those with one or less drug holiday (35). In another study, intermittent use of
cART in the first year of therapy was significantly associated with increased
mortality (36).
Results from prospective randomized controlled trials on structured
treatment interruptions confirm that patient non-persistence adversely affects
clinical outcomes in HIV-infected patients eligible for cART. In one trial,
scheduled treatment interruptions exceeding 4 weeks were associated with
development of resistance (37). In another study, a structured “1-week-on-1week-off” treatment strategy using cART was associated with increased
likelihood of virological failure, and development of resistance among the
patients taking an NNRTI-based regimen (15); these findings suggest that even
missing one week of therapy has significant adverse consequences. In the
randomized controlled SMART trial, planned cART discontinuation using a
priori CD4 guidance thresholds was associated with increased rates of HIV- and
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non-HIV-associated morbidity, decreased levels of HIV suppression, and lower
CD4 counts, when compared to those who persisted with therapy (1).
On the other hand, in a randomized controlled treatment strategy of “fiveday-on, two-day-off” schedule of therapy in patients with durable virological
suppression, 11 - 22% experienced virological failure among patients on a
nevirapine- or PI-based regimen, however, no failure was observed among those
on efavirenz-based regimens over 48 weeks of observation (14). Parienti and et
al., using an observational analytical approach, demonstrated that frequent and
longer duration of treatment interruption (non-persistence) were better
predictors of virological rebound (i.e. failure) among patients on an NNRTIbased regimen (38, 39). According to their logistic model, a treatment
interruption of 15 days was associated with a 50% probability of virological
rebound among those on an NNRTI-based regimen. On the other hand, higher
average adherence rates overall appeared to be a better correlate of virological
suppression among those on a boosted-PI-based regimen. These last two studies
suggest that there may be unique properties of one or more of the components of
the cART regimen that contributes to different permissible gaps in treatment
interruptions that affect adverse clinical consequences
In sum, these data highlight that permissible gaps in HIV treatment may
be as short as a few days and also vary depending on the unique
pharmacokinetic and genetic barrier to resistance profiles of the various
components of a cART regimen.

Regimen Persistence
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Though reported measurements have been imperfect, persistence of an
initial antiretroviral ranges from 11.8 months (40) to 34.3 months (41) with the
trend toward longer persistence in more recent years. Though newer salvage
regimens have resulted in markedly improved levels of viral suppression, it
remains true that maintaining a patient on the initial regimen is likely to result in
the greatest likelihood of virological suppression. Compared to the initial
regimen, the second and the third regimens have significantly lower probability
of achieving virological suppression (adjusted odds ratio 0.49 and 0.22,
respectively, and p<0.02 for both) (41). Furthermore, each modification is
associated with a more complex dosing schedule, a less favorable toxicity profile,
and also decreased persistence of the subsequent regimen (41). In another study,
patients who started on a persistent, NNRTI-based regimen were less likely to
experience subsequent regimen modifications and a three-class regimen,
compared to a less-persistent, PI-based regimen (42).
Regimen persistence is a particularly important issue in resource-poor
settings, where available antiretroviral choices are limited and the medication
alternatives are costly (39). Virological failure due to resistance to therapy may
leave patients with few or no remaining treatment options.

Factors that Affect Persistence
Adherence, patient persistence, and regimen persistence are intimately
inter-related; they may be influenced by not only a similar set of patient,
medication, and socioeconomic characteristics, but also by one another. For
example, low adherence and frequent patient non-persistence due to toxicity of a
regimen may lead to development resistance. Subsequent virological failure will
19

eventually result in modification of the patient’s regimen, leading to decreased
regimen persistence. Existing literature on patient and medication characteristics
that impact patient and regimen persistence is summarized below.

Patient Characteristics
In the treatment of HIV infection, many patient characteristics contribute
to decreased persistence. Clinical characteristics of patient-associated factors that
have been associated with decreased patient persistence include female gender,
high HIV RNA level, current substance use disorder (33), depression, and shorter
time on cART (43). Younger age and black race have also correlated with
decreased patient persistence (43).
Patient

characteristics

associated

with

regimen

persistence

are

summarized in Table 2. These include: high or increasing HIV RNA levels (4347), low CD4 count prior to cART initation (46, 48), current high CD4 count (49,
50), short duration on therapy (51), previous cART experience (40, 51) history of
opportunistic infection (52), and hepatitis C virus co-infection (53) .
Also, affective mental disorders (41), depression (43, 47), use of alternative
medicine, hospitalization (51), female gender (44, 50), men who have sex with
men (50), black or minority race/ethnicity (38, 43, 54), younger age (43), low
weight (48), lack of medical coverage (54, 55), and incarceration (56-58) have been
associated with decreased regimen persistence.
Co-morbidities such as mental illness and substance use disorders are
common among HIV-infected patients, and these patients frequently transition
through correctional facilities (59, 60). Non-persistence is a great challenge in this
population both within community and upon transition between a correctional
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and a community setting. (57, 61, 62). In a study among HIV-infected prisoners,
95% of released inmates failed to fill their cART prescription within 10 days of
release (the time period for which medications were provided upon release), and
patients therefore presumably did not take HIV medications beyond this period
(61). Others have confirmed that HIV-1 RNA levels increase during this postrelease period; the finding that the HIV-1 RNA levels return to their pretreatment levels, and not just a partial increase, suggest that non-persistence
rather than non-adherence is the mechanism of poor treatment outcomes (57). In
another study of jail detainees, only 15% of those who were re-incarcerated
repeatedly persisted with their medications. Those who did not persist or who
were never prescribed medications had increased likelihood of having higher
HIV-1 RNA levels and decreasing CD4 counts (62). This suggests that patient
non-persistence after release from prison or jail is common and is an important
public health concern.

Medication Characteristics
Existing data assessing the characteristics of a specific medication
component or entire cART regimen on persistence primarily focus on regimen
persistence. Medication characteristics associated with regimen persistence are
summarized in Table 2. In Western countries, adverse events associated with
cART and treatment failure were the two most common reasons for medication
discontinuation or modification (44, 63). In addition, a greater number of
medications within a regimen (45) and a more frequent dosing (41) were
associated with early regimen discontinuation. In developing countries, in
addition to adverse events and treatment failure, high cost and inadequate
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supply

of

medications

were

cited

as

common

reasons

for

regimen

discontinuation among patients (51, 64).
Characteristics of individual antiretroviral medications within a cART
regimen also influence regimen persistence. Overall, NNRTI-based regimens
have been associated with increased persistence, compared to boosted or
unboosted PI-based, triple-NRTI-based, or triple-class regimens (41, 65-67).
Newer generations of NRTIs such as tenofovir, lamivudine, emtricitabine, and
abacavir improve persistence compared to zidovudine, stavudine, and
didanosine (41, 49, 50). Also, efavirenz has been associated with increased
regimen persistence compared to nevirapine, and also the protease inhibitors
lopinavir, saquinavir, and indinavir (33, 49, 64, 67). Among PIs, darunavir and
atazanavir were less likely to result in regimen switch due to toxicity (50, 68),
whereas

lopinavir,

saquinavir,

and

ritonavir

were

associated

with

discontinuation or modification of therapy (43, 44, 50).
In a recent trial in which patients were randomized to receive coformulated tenofovir/emtricitabine or abacavir/lamivudine plus efavirenz or
atazanavir boosted with ritonavir, lower rates of virological failure and increased
persistence were observed among the group assigned to tenofovir/emtricitabine
compared to abacavir/lamivudine (69).

Adverse consequence of abacavir

resulted in medication discontinuation at a higher rate than for tenofovir.

Healthcare Setting Characteristics
The organization of healthcare and even pharmacy services for patients
impacts persistence. For example, the frequency with which either clinicians
choose to follow their patients or even how it is dictated by insurance or
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managed healthcare providers can negatively influence persistence.

Prior

authorization for medication changes has been associated with patient nonpersistence (70), as has co-pays and requirements for patients to spend down
their personal resources before prescription benefits are renewed (71). Most
patients who become non-persistent do so without their provider actually
knowing it until the patient’s next scheduled appointment (if the patient
manages to return at all). In the case of HIV-infected drug users, the onsite
integration of buprenorphine treatment into HIV treatment settings resulted in
improved retention in care and continuation of medications compared to those
who were referred for treatment for their opioid dependence off-site (72). Thus,
organizational factors may contribute either to fragmented healthcare or less
frequent monitoring, especially early in cART initiation, may disrupt continuity
of cART and worsen HIV treatment outcomes.

Persistence in Directly-Administered Antiretroviral Therapy among HIVinfected drug users
Patient and regimen non-persistence defined and whose relevance to
clinical and investigational considerations of HIV medication has been
demonstrated above, were studied among HIV-infected injection drug users
undergoing DAART in a randomized controlled setting. Results from this study
are presented here.

Patterns of Non-Persistence
Of the 74 participants who initiated DAART in Project Trust, 15 (20%)
were completely persistent, not missing 3 or more days, during the 6-month
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intervention period. The patterns of non-persistence are described in Table 3.
Among the 59 (80%) participants who were non-persistent for ≥ 3 days, the mean
and median numbers of non-persistence episodes were 2.66 [standard error (SE):
± 0.42] and 1.0 [interquartile range (IQR) 1–3], respectively. The mean and
median lengths of non-persistence gaps were 15.0 (SE: ± 2.08) and 4.0 (IQR 3–6)
days, respectively. Kaplan– Meier estimates for the time to first non-persistence
gap, stratified by length of treatment lapses in therapy, are presented in Fig. 3.

Factors Associated with Patient Non-Persistence
Demographic, psychosocial, and medication characteristics along with
other factors thought to be associated with patient non-persistence are presented
in Table 4. Depression (CES-D≥16) was significantly associated with nonpersistence ≥ 3 days (AOR= 17.4; 95% CI: 1.5 – 204.1, p= 0.02).

Similarly,

univariate analyses for non-persistence ≥ 7 days were significantly associated
with having depression (OR=7.2; 95% CI: 1.5 – 35.7, p= 0.02) and having high
addiction severity (OR=3.9; 95% CI: 1.5 – 10.2, p < 0.01).

The statistical

significance for these outcomes was preserved in multivariable analysis for both
depression (AOR=5.4; 95% CI: 1.1 – 27.5, p= 0.04) and high addiction severity
(AOR=3.2; 95% CI: (1.1 – 9.2, p= 0.03).

No other factors were significantly

associated with non-persistence ≥ 3 or ≥ 7 days. Non-persistence ≥ 5 days was
not significantly associated with any identified covariates.
Of the 59 DAART participants who had any type of predefined nonpersistence, 31 (52.5%) had 2 or more episodes of non-persistence (Table 4).
Univariate analyses showed statistically significant associations with injection
drug use (OR=7.1; 95% CI: 1.4 – 36.9, p= 0.02), low self-efficacy (OR=0.3; 95%CI:
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0.1 - 0.9, p= 0.03), and high-confidence in taking medications as prescribed
(OR=0.3; 95% CI: 0.01 – 0.80, p=0.02). In multivariate analysis, and injection drug
use (AOR=15.2; 95% CI:1.8 – 129.1, p= 0.02) was significantly associated with
recurrent non-persistence. Twice daily dosing had a trend towards an increased
risk of recurrent non-persistence compared to once daily dosing (AOR= 6.3, 95%
CI:1.0 – 40.0, p= 0.05).

Correlates of Virological Success
In a univariate linear analysis, there was no statistically significant
association between virological success and non-persistence (data not shown).

Regimen Non-Persistence
Among the 74 DAART participants, 20 (26%) modified their antiretroviral
regimen during the 6-month intervention period and were thereby defined as
having regimen non-persistence.

Of the demographic and psychosocial

characteristics, only low social support (AOR=2.9; 95% CI: 1.0 – 8.4, p < 0.05) was
statistically associated with regimen non-persistence. Time to regimen nonpersistence was significantly shorter for NNRTI-based regimen compared to a
PI-based regimen (HR=3.0; 95% CI: 1.1 – 7.9; p= 0.03). No significant relationship
between regimen non-persistence and patient non-persistence was observed.

5. Discussion
Definition of medication persistence and review of literature
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Much of research on HIV medication-taking behavior continues focus on
adherence and mistakenly incorporates elements of persistence into its construct.
Adherence and persistence are similar in that both constructs measure
accordance of patient behavior with a prescribed therapy. In contrast to
adherence, persistence is a longitudinal measure of antiretroviral therapy, with
the emphasis on continuity rather than frequency.
In this thesis, we define medication persistence in the setting of HIV
treatment and present patterns of non-persistence among HIV patients
undergoing directly administered antiretroviral therapy.

We deconstruct

persistence into two types: patient persistence and regimen persistence. The
former measures continuous adherence to cART without exceeding a permissible
gap, and the latter measures duration of a pre-specified cART regimen.
As cART regimens become more tolerable, less complex and are created
with higher barriers to development of resistance, interventions designed to
improve medication-taking behaviors need to increasingly focus on nonpersistence in addition to non-adherence. Such interventions will likely need to
incorporate measurement of persistence in real-time so that lapses in medicationtaking are averted promptly.
As summarized here, patient non-persistence is associated with adverse
clinical outcomes, including higher rates of treatment failure, development of
drug resistance, and increased mortality. Importantly, a longer duration and a
higher frequency of patient non-persistence appear to increase the risk of adverse
outcomes.
Patient non-persistence is of a major public health concern because viral
resistance may develop during non-persistent periods and subsequently require
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a more costly and toxic regimen for viral suppression. Furthermore, a higher
viral load observed during non-persistent periods increases the risk of
transmission of a potentially drug-resistant virus, if the patient engages in a risky
behavior.
In addition to interventions that address patient characteristics associated
with decreased persistence and clinical outcomes, such as substance abuse,
incarceration, mental illness, and depression, new approaches may benefit both
patients and the public. For example, a system in which failure of a patient to
refill his or her medication in a scheduled time period leads to notification of his
or her healthcare provider by the pharmacy would enable the physician to
address the persistence issue with the patient and may prevent the patient from
being non-persistent. Additionally, an improved coordination between a
correctional and a community healthcare system would help many recently
incarcerated HIV patients to remain persistent with therapy. Education of
clinicians and patients of importance of continuous adherence, and impact of
non-persistence and “drug holidays”, especially for NNRT-based regimens, may
lead to a better decision-making with regards to selection and continuation of
therapy. Adherence tools, such as schedules, dosettes, and electronic reminder
systems, may also increase both adherence and persistence (73). Finally, in
patients with a high risk of non-adherence and non-persistence may benefit from
a directly observed therapy (20, 74, 75).
Each regimen change is associated with a diminished chance of viral
suppression as well as higher toxicity and cost, and thus regimen persistence is
an important issue from both clinical and public health perspectives. As
summarized in this thesis, fewer drugs in a regimen, fixed-dose combinations,
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newer generations of NRTIs, boosted-PIs, and efavirenz correlate with greater
regimen persistence. Consideration of effects of each antiretroviral on regimen
persistence is needed to maximize chances of prolonged viral suppression.
Limited availability of antiretroviral medications makes regimen
persistence

an

especially

important

issue

in

resource-limited

settings.

Additionally, inconsistent supply of drugs may be a hindrance to patient as well
as regimen persistence. Unfortunately, newer generations of antiretrovirals
associated with increased persistence tend to be more costly and unavailable in
developing countries.
Last, the improved adherence with contemporary treatment regimens and
data from the SMART trial remind clinicians and researchers that persistence,
has become the “Achilles Heel” of HIV treatment and interventions that retain
patients on effective treatment are urgently needed.

Patterns of non-persistence in HIV-infected drug users receiving DAART in a
randomized-controlled trial
We found a high rate of patient non-persistence among HIV-infection
drug users receiving DAART. Among 74 subjects, 59 (80%) were non-persistent
with therapy for 3 or more consecutive days, and 33 subjects (45%) for ≥7
consecutive days. Thirty-one patients (42%) had more than one episode of nonpersistence lasting ≥3 days. These rates of medication non-persistence are higher
than previously reported among diverse population within cohorts (31, 32, 34,
35, 76).
Several factors may be contributing to the high rate of non-persistence
reported in this paper. First, our sample includes only active drug users and
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drug users have been demonstrated to have problematic adherence to therapy
(77, 78). This study also confirms that drug use, even in the setting of an
evidence-based adherence intervention, is associated with problematic nonpersistence. Second, patient persistence data obtained through self-report in
other studies may unrealistically underestimate the true frequency and length of
non-persistent events, despite some studies suggesting adherence patterns can be
accurately reported (79).
In analysis of factors associated with non-persistence, high levels of
addiction severity and depression were associated with an increased risk of nonpersistence. Additionally patients actively using injection drugs were more like
to have multiple episodes of non-persistence. These results are consistent with
other studies that have correlated active drug use and underlying psychiatric
disorder with treatment interruptions, non-adherence, and poor HIV treatment
outcomes (33, 77, 78, 80, 81)
In this thesis, we did not find a significant association between patterns of
patient non-persistence and virologic success, which is contrary to findings
reported in previous studies reviewed here (31, 34, 35). Failure to find an
association between non-persistence and virologic success in this study may be
attributed to several factors.
First, the small sample size likely resulted in an inadequate power avoid a
Type II error. Second, both persistence and virologic outcome data were limited
to 6 months of intervention, and it is possible that this period may have been
insufficiently long enough to detect a statistically significant association, in
contrast to other studies in which patients were followed for years. Third, the
impact of non-persistence on virologic outcomes is likely different depending on
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a patient’s antiretroviral regimen. Because of a low genetic barrier to resistance
development as well as long half-lives of NNRTI’s, it is hypothesized that longer
term non-persistence may have a greater negative impact on patients on an
NNRTI-based regimen than those on a PI-based one; however, short treatment
gaps may favor NNRTI-based regimens due to their longer half lives (38). A high
proportion (60%) of patients on a PI-based regimen in this cohort may have
required a greater power to detect a statistically significant association between
non-persistence and virologic outcomes.
In analysis of factors associated with non-persistence, high levels of
addiction severity were associated with an increased risk of non-persistence of 7
days or more. Additionally, patients actively injecting drugs were more like to
have multiple episodes of non-persistence. This study is the first to confirm the
association of active drug use and severity on non-persistence in patients
receiving DAART.
Previous studies have reported that active drug users are at an increased
risk of treatment interruptions (33), non-adherence (80) , and poor HIV treatment
outcomes (77, 78). Our findings that patients with high levels of addiction
severity and active use are at an increased risk of non-persistence and recurrent
episodes of treatment gaps are consistent with existing literature, and therefore
not surprising. Because of the grave impact active drug use has on adherence,
persistence, and HIV outcomes, a substance dependence treatment program
must be considered as an integral part of HIV treatment for active drug users.
Buprenorphine/naloxone integrated into HIV treatment settings has shown
promising results, and was associated with improved HIV treatment outcomes
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among opioid-dependent patients infected with HIV, especially those treated for
longer durations (82).
HIV-infected patients with substance use disorders frequently have an
underlying psychiatric disorder (60, 83). Since depression has been linked to
decreased adherence and shorter survival as well as increased treatment
interruptions (81), it is not surprising that patients with higher levels of
depressive symptoms were less persistent with therapy. Incorporation of
effective pharmacotherapy and counseling, as has been shown among homeless
persons with HIV (84), in addition to treatment of active drug use, would benefit
patients triply diagnosed with HIV, substance use, and depression.
Finally, PI-based regimens were associated with increased regimen
persistence compared to NNRTI-based regimens. This finding is also inconsistent
with existing literature that NNRTI-based regimens tend to be more persistent
than PI-based, triple-NRTI-based, or triple-class regimens (41, 65-67). One
explanation for these results is that among drug users with high rates of nonadherence and non-persistence, PI-based regimens may yield favorable
treatment outcomes due to the shorter half-lives and higher genetic barrier to
resistance development of PIs compared to NNRTIs; however, due to
unavailability of data on reasons explaining regimen non-persistence (i.e.
regimen modification), we cannot determine if this is in fact the case in this
study.
There are several important limitations to this study. The study
population was small, restricted to a single inner-city community, and studied
among those who received antiretroviral therapy via direct observation. This
limits the generalizability of these findings. Furthermore, the analyses presented
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here were not part of preplanned analyses comparing randomized groups. As
such, the inferences made here must be considered as tentative and hypothesisgenerating rather than definitive. Patients who dropped out were considered
non-persistent for the remaining duration of the study, although it is possible
that they resumed or continued therapy in a non-research setting. Finally, pillpocketing or non-adherence to MEMS caps instructions, and associated bias in
persistence data cannot be excluded.
Further prospective studies are therefore needed to better understand
both patient and regimen persistence, factors associated with them, and their
impact on HIV treatment outcomes.
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6. Figures

Figure 1. Schematic figure outlining the relationship between medication
adherence and the risk of developing PI or NNRTI drug resistance. NNRTItreated individuals rarely develop resistance at high levels of adherence due to
the virological effectiveness of these regimens. NNRTI resistance develops
rapidly at moderate to low levels of resistance due to the low ‘fitness’ costs
associated with single mutations. Single PI-treated individuals may develop
resistance at high levels of adherence because residual viral replication is often
seen in such patients. PI resistance is uncommon at low levels of adherence
because of the significant fitness costs associated with these mutations.
Resistance to a ritonavir- boosted PI is only possible in a narrow range of
adherence where there is sufficient drug around to select for mutations that
reduce ‘fitness’ while still allowing residual viral replication. Data in this figure
are conceptual and based on trends observed in a number of recent studies (see
text). PI, protease inhibitor; NNRTI, non-nucleoside reverse transcriptase
inhibitor.
Reprinted from “Paradoxes of adherence and drug resistance to HIV
antiretroviral therapy” by Bangsberg DR, Moss AR, Deeks SG. 2004 J Antimicrob
Chemother 53: 696-699.
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Figure 2. The relationship between patient persistence, regimen persistence, and
adherence. Adherence levels are shown as a solid line and HIV-1 RNA levels as a
dashed line. The dotted line represents optimal HIV viral suppression.
PNP*= patient non-persistence
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Figure 3. Time to patient non-persistence among DAART subjects, stratified by
the length of non-persistence. A subject was categorized as “non-persistence ≥ 3
days” if he missed 3 or more consecutive days of antiretroviral medications at
any point during the DAART intervention period. Non-persistence ≥ 5 days and
non-persistence ≥ 7 days were defined similarly. Each Kaplan-Meier failure curve
represents the same population of subjects (N=74).
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Figure 4. Time to regmien non-persistence among DAART subjects, stratified by
the antiretroviral therapy backbone on the first day of DAART (N=74). Regimen
non-persistence was defined as any change in antiretroviral medication during
the intervention period of the study. The p-value was calculated with Cox
proportional-hazards regression. (Legend: NNRTI = non-nucleoside reverse
transcriptate inhibitors; PI = protease inhibitor)
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7. Tables
Table 1: Methods and Study Types to Measure Persistence
Prospective
Patient Persistence
Directly Observed Therapy
MEMS cap
Patient recall
Pharmacy refill records
Medical record review (e.g., notation
of change or discontinuation)
Reason for patient non-persistence
(e.g., time gap)
Questions on a study instrument
Review of medical records (e.g.
adverse effects)
Regimen Persistence
Regimen change form on a study
instrument
Patient recall
Pharmacy refill records
Medical record review (e.g., notation
of change or discontinuation)
Reason for regimen non-persistence
(e.g., regimen change)
Questions on a study instrument
Review of medical records (e.g., viral
load, adverse effects)

X
X
X
X

Retrospective

X
X

X
X
X
X
X

X
X

X
X
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Table 2: Summary of Recent Studies on Regimen Persistence
Study, Sample

Factors associated with

Factors associated with

Reasons for

Size, Study

decreased regimen persistence

increased regimen

regimen

persistence

change or

Design, Time
Period & Location
Vo et al., 2008 (49)

discontinuation
ddI/another NRTI (ref:

TDF/FTC or TDF/3TC

Reasons for

N=1866

ZDV/3TC; aRRR: 2.06; 95%

(ref: ZDV/3TC;

regimen

Sub-analysis study

CI: 1.29-3.31)

aRRR: 0.65; 95% CI:

change

0.43-0.97)

included

in a prospective
cohort study
2000-2005
Switzerland

IDV/r (ref: EFV; aRRR: 2.28;
95% CI: 1.24-4.17)

intolerance

HIV RNA >5 log10 copies/mL

(51%), patient

(aRRR: 1.35; 95% CI: 1.07-

wish (15%),

1.71)

doctor decision
(15%), and

CD4 count >350 cells/µl (ref:

virological

200-350 cells/µl; aRRR: 1.50;

failure (7%).

95% CI: 1.04-2.17)
Lodwick et al.,
2008 (50)
N=508
Retrospective
study of existing
medical records
2000-2005 UK

d4T (ref: ZDV; IRR: 1.67;
95%CI: 1.28–2.17)
LVP (ref: EFV; IRR: 1.53; 95%
CI: 1.21-1.94)
SQV (ref: EFV; IRR: 1.75, 95%
CI: 1.04–2.95)
Higher CD4 count (for 100

ABC (ref: ZDV; IRR:
0.29; 95% CI: 0.120.67)
TDF (ref: ZDV; IRR:
0.61; 95% CI: 0.480.79)
Heterosexual men (ref:

cells/µl increase; IRR: 1.06;

homosexual men or

95% CI: 1.02-1.11)

heterosexual
women; p<0.05)
Longer viral
suppression (per
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two-fold longer
time; IRR: 0.90; 95%
CI: 0.85-0.86)
Willig et al., 2008
(41)
N=542

Affective mental disorder
(aHR: 1.43; 95% CI: 1.06-1.93)
Twice-daily dosing (ref: once

Retrospective

daily; aHR: 1.92; 95% CI:

study of existing

1.29-2.88)

medical records
2000-2007 USA

ddI or d4T (ref: ABC or TDF;
aHR: 2.16; 95% CI: 1.09-4.26)
Triple NRTI (ref: NNRTI; aHR:
1.76; 95% CI: 1.14-2.73)
Unboosted PI (ref: NNRTI;
aHR: 1.58; 95% CI: 1.02-2.46)
Boosted PI (ref: NNRTI; aHR:
1.57; 95% CI: 1.02-2.41)

Braithwaite et al.,
2007 (67)
N=6394
Retrospective
study of existing
medical records

Single PI (ref: EFV, aHR: 1.16;
p=0.003)
Triple NRTI (ref: EFV, aHR:
1.22; p=0.011)
d4T/3TC (ref: ZDV/3TC, aHR:
1.08 p=0.032)

1996-2004 USA
Li et al., 2005 (43)

Younger age (per 5 year

N=687

decrease; aOR: 1.20; 95% CI:

Nested cohort

1.03-1.40)

study of a

High HIV RNA level (per 1

multicenter

log10 increase; aOR: 1.42; 95%

prospective cohort

CI: 1.17-1.72)
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study
1997-2001 USA

Depression (aOR: 2.03; 95% CI:
1.24-3.32)
ABC (aOR: 1.82; 95% CI: 1.033.20)
LPV (aOR: 4.68; 95% CI: 1.5613.99)

Pence et al., 2008

Minority race/ethnicity (aHR:

(85)

2.44; 95% CI: 1.33-4.49;

N=435

p<0.05)

Sub-analysis of a
prospective cohort
study
2001-2002 USA
Kiguba et al., 2007
(51)
N=686
Cross-sectional
study
2005-2006 Uganda

Previous cART experience
(aOR: 3.70; 95% CI: 2.13-6.25)
Use of alternative medicines
(aOR: 2.18; 95% CI: 1.06-4.47)
Hospitalization (aOR: 2.36;
95% CI: 1.32-4.20)
One year or less on cART

Reasons for
discontinuation
of cART
included high
cost (43.0%),
adverse events
(21.1%), drugs

(aOR: 11.11; 95% CI: 5.00-

being out of

25.00).

stock (10.5%).

Being unmarried (aOR: 1.64;
95% CI: 1.02-2.70)
3 months or less on cART

Reasons for
modification of
cART were

(aOR: 3.13; 95% CI: 1.16-

adverse events

8.33).

(71.8%) and
high cost
(23.3%).
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Kumarasamy et

NVP (ref: RTV or EFV),

Reasons for

al., 2006 (64)

median 66 vs. 131 days;

regimen

N=1443

p=0.150).

modification

Retrospective

included

study of existing

adverse events

medical records

(64%) and cost

1996-2004 India

(19%).
Reasons for
regimen
discontinuation
included cost
(64%) and
adverse events
(21%).

Willig et al., 2009
(48)
N=546
Retrospective
study of existing

Weight < 60kg (aHR: 1.77; 95%
CI: 1.25-2.51)
Baseline CD4 <200 (aHR: 1.73;
95% CI: 1.03-2.91)

after initiation of
therapy (aHR: 0.52;
95% CI: 0.28-0.95)

ZDV use at in the first 120

medical records

days of therapy (aHR: 2.09;

2004-2007 Peru

95% CI: 1.22-3.57)

Sax et al., 2009

ZDV use >120 days

ABC-3TC (ref: TDF-FTC; HR:

(69)

1.87; 95% CI (1.38-2.54);

N=1858

p<0.001)

Partially blinded
randomized
controlled trial
2006-2009 USA
Domingo et al.,

LPV/r (ref: EFV, HR: 2.10, 95%
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2008 (86)

Cl (1.40-3.15), p=0.0003)

N=1550
Sub-analysis of a
prospective cohort
study
1999-2007 Spain
Springer et al.,

Three class regimen (ref: Triple

2007 (65)

NRTI, NRTI-based, or PI-

N=1099

base regimen; p<0.05)

Retrospective
cohort study
1999-2002 USA
MacArthur el al.,

Three class regimen (ref:

Most common

2006 (66)

NRTI-based or PI-base

adverse effects

N=1397

regimen; HR: 1.58; p<0.0001)

cited as a

Randomized

reason for

controlled trial

discontinuation

1999-2002 USA

were nausea or
vomiting,
diarrhea, and
rash.

Abbreviations: 3TC, lamivudine; ABC, abacavir; aHR, adjusted hazard ratio; aOR, adjusted odds
ratio; ATV, atazanavir; CI, confidence interval; d4T, stavudine; ddI, didanosine; EFV, efavirenz;
FTC, emtricitabine; cART, combination antiretroviral therapy; HIV, human immunodeficiency
virus; HR, hazard ratio; IDV/r, indinavir/ritonavir; IRR, incidence rate ratio; LPV, lopinavir;
LPV/r, lopinavir/ritonavir; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor; NVP, nevirapine; OR, odds ratio; PI, protease inhibitor;
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RNA, ribonucleic acid; aRRR, adjusted relative risk ratio; RTV, ritonavir; SQV, saquinavir; TDF,
tenofovir; ZDV, zidovudine

43

Table 3. Patterns of patient non-persistence among subjects receiving directly
administered antiretroviral therapy.
Non-persistence

Non-persistence

Non-persistence

≥ 3 days

≥ 5 days

≥ 7 days

59 (80%)

41 (55%)

33 (45%)

PI (n=44)

35 (80%)

23 (52%)

20 (45%)

NNRTI (n=22)

17 (77%)

12 (55%)

7 (32%)

Other (n=8)

7 (87.5%)

6 (75%)

6 (75%)

QD (n=21)

15 (71%)

10 (48%)

9 (43%)

BID or more (n=53)

44 (83%)

31 (58%)

24 (45%)

<10 pills daily (n=40)

50 (83%)

35 (58%)

29 (48%)

≥10 pills daily (n=34)

9 (64%)

6 (43%)

4 (29%)

All (n=74)

Frequency of Dosing

Pill Burden

A subject was categorized as “non-persistence ≥ 3 days” if he missed 3 or more consecutive days
of antiretroviral medications at any point during the DAART intervention period. Nonpersistence ≥ 5 days and non-persistence ≥ 7 days were defined similarly.
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Table 4. Adjusted odds ratios of factors associated with patient nonpersistence among subjects receiving directly administered antiretroviral
therapy.
Non-persistence ≥

Non-persistence ≥

Recurrent episodes

3 days

7 days

of gaps (≥ 3 days)

Homeless
No (n=45)

Referent

Yes (n=29)

0.10 (0.01 – 1.01)

Drug Abuse Severity (DAST-10)
Low or moderate (n=38)

Referent

High (n=36)

3.17 (1.1 – 9.14)*

Injection drug use in past 30 days
No

Referent

Yes

15.20 (1.79 –
129.11)*

Depression (CES-D≥16)
No (n=14)

Referent

Referent

Referent

Yes (n=55)

17.38 (1.48 –

5.41 (1.06 – 27.53)*

2.89 (.60 – 13.95)

204.13)*
Preference for medication taking
Prefers assistance (n=18)
Prefers no assistance (n=53)

Referent
0.30 (0.04 – 2.59)

Baseline viral load
VL<400 copies/mL (n=21)

Referent

VL≥400 copies/mL (n=53)

2.73 (0.67 – 11.23)

Social Support
High

Referent

45

Low

3.29 (.84 – 12.87)

Self-Efficacy
High

Referent

Low

0.37 (.11 – 1.28)

Frequency of dosing
Once daily

Referent

Twice daily

6.32 (1.00 – 39.98)

Confidence can take medications
as prescribed
9 or 10 (Extremely confident)
8 or lower

Referent
.40 (.10 – 1.60)

Univariate analysis between the following variables in non-persistence ≥ 3, ≥ 5, and ≥ 7 days, and
recurrent episodes of gaps ≥ 3 were performed. Age, gender, race, homelessness, education, drug
abuse screening test, CES-D score, social support, self-efficacy, confidence that one can take
medications as prescribed, preference for assistance with medication-taking, willingness to travel
for DAART, frequency of dosing, pill burden, and baseline viral load. Those variables with a pvalue <0.10 on univariate analysis were included in the multivariate logistic regression and their
adjusted odds ratios are presented here. Analyses for non-persistence ≥ 5 are not shown because
no univariate association had a p –value <0.10.
*p<0.05
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